



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

9th February 2023

Corporate Relationship Department
M/s. BSE Ltd.
Dalal Street, Fort
Mumbai – 400 001.
Scrip Code: **524816**

The Manager – Listing
M/s. National Stock Exchange of India Ltd.
Exchange Plaza, Bandra-Kurla Complex
Bandra(E), **MUMBAI – 400 051.**
Scrip Code: **NATCOPHARM**

Dear Sir/Madam,

Sub: Outcome of Board Meeting

We would like to inform you that the Board of Directors of the Company at their meeting held today have considered and approved the following along with other items of business:

1. Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended 31st December, 2022 prepared under Indian Accounting Standards (IND-AS) and as per Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time ("Listing Regulations") along with Limited Review Report of the Statutory Auditors. Please find enclosed herewith the copy of the same for your information.
2. Declared 3rd interim dividend of Rs.1.25 (one rupee twenty-five paise only i.e., 62.50%) each per equity share of Rs.2/- (Rupees two only) each for the financial year 2022-23. The date for taking on record of its shareholders eligible for the purpose of payment of 3rd interim dividend i.e., record date is fixed as **Tuesday, the 21st day of February, 2023**. The payment of said interim dividend will be from 1st March, 2023.
3. The Board of Directors have approved to make the investment for an amount not exceeding Rs.13 Crores (6.68% of the capital on a fully diluted basis) in M/s. Redcliffe Hygiene Private Limited. Brief disclosure under Regulation 30 and sub-para (1) of para (A) of part (A) of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is enclosed.

A Copy of Press release is also enclosed for your information.

We are also updating the financial results on the website of the Company.

Meeting commenced at 12.33 p.m. and concluded at 1.40 p.m.

Thanking you

Yours faithfully,
For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer

Encl: As above